Memantinum

Description
A derivative of Amantadine; a modulator of the glutamatergic system.
Indications
Moderate to severe Alzheimer’s disease.
Contraindications
Confusion; severe IFN; epilepsy, increased sensitivity to Memantine.
Dosage
For adults. Oral administration. During the 1st week, 5 mg per day taken in the first half of the day, then increase the dose by adding an additional 5 mg weekly up to 20 mg.
For children. Spasticity of central origin: maintenance dose orally – 0.5 mg/kg.
For elderly. Administer with caution.
IFN. Reduce the dose.
KFN. Administer with caution.
Adverse reactions
Most common: dizziness, anxiety, agitation, fatigue, disrupted sleep; sensation of pressure in the head; nausea.
Others: seizures may increase in patients with epilepsy.
Pregnancy
Not recommended for use.
Breastfeeding
Do not breastfeed.
Warnings
Unknown if the drug is safe for pregnant and lactating women.
Not recommended for use in conjunction with Amantadine.

Source | Drug Guide | Lithuanian University of Health Sciences | Institute of Physiology and Pharmacology | Doctor of Medical Sciences Rimas Jankūnas, Doctor of Medical Sciences Arvydas Milašius | Clinic of Internal Diseases | Doctor of Medical Sciences Palmira Leišytė